Table 5. Cost effectiveness analysis for standard care and antimicrobial resistance point-of-care test strategies.
| Subgroup | Comparison | Total additional costa | Additional cost per patienta | Number of optimal treatments gained | Additional cost per optimal treatment gaineda | Number of ceftriaxone treatments avoided | Additional cost per ceftriaxone-sparing treatmenta |
|---|---|---|---|---|---|---|---|
| All | AMR POCT A vs SC | GBP 1,098,386.00 (EUR 1,468,860.00) |
GBP 28.26 (EUR 37.79) |
895 | GBP 1,226.97 (EUR 1,640.81) |
0 | Dominated |
| AMR POCT B vs SC | GBP 1,237,676.00 (EUR 1,655,131.00) |
GBP 31.84 (EUR 42.58) |
1,660 | GBP 745.44 (EUR 996.87) |
0 | Dominated | |
| AMR POCT C vs SC | GBP 1,210,330.00 (EUR 1,618,562.00) |
GBP 31.14 (EUR 41.64) |
1,449 | GBP 835.39 (EUR 1,117.16) |
0 | Dominated | |
| AMR POCT D vs SC | GBP 415,516.00 (EUR 555,665.30) |
GBP 10.69 (EUR 14.30) |
1,002 | GBP 414.67 (EUR 554.53) |
36,790 | GBP 11.29 (EUR 15.09) |
|
| AMR POCT E vs SC | GBP 601,414.00 (EUR 804,264.80) |
GBP 15.47 (EUR 20.69) |
895 | GBP 671.82 (EUR 898.42) |
26,214 | GBP 22.94 (EUR 30.68) |
|
| MSM | AMR POCT A vs SC | GBP 620,274.00 (EUR 829,486.10) |
GBP 28.30 (EUR 37.85) |
499 | GBP 1,242.13 (EUR 1,661.09) |
0 | Dominated |
| AMR POCT B vs SC | GBP 697,730.00 (EUR 933,067.20) |
GBP 31.84 (EUR 42.58) |
1,001 | GBP 697.32 (EUR 932.52) |
0 | Dominated | |
| AMR POCT C vs SC | GBP 683,317.00 (EUR 913,792.80) |
GBP 31.18 (EUR 41.70) |
864 | GBP 790.97 (EUR 1,057.76) |
0 | Dominated | |
| AMR POCT D vs SC | GBP 235,532.00 (EUR 314,974.50) |
GBP 10.75 (EUR 14.38) |
568 | GBP 414.38 (EUR 554.15) |
20,676 | GBP 11.39 (EUR 15.23) |
|
| AMR POCT E vs SC | GBP 358,920.00 (EUR 479,980.00) |
GBP 16.38 (EUR 21.90) |
499 | GBP 718.75 (EUR 961.18) |
13,842 | GBP 25.93 (EUR 34.68) |
|
| MSW | AMR POCT A vs SC | GBP 239,316.00 (EUR 320,034.80) |
GBP 28.26 (EUR 37.79) |
248 | GBP 965.92 (EUR 1,291.72) |
0 | Dominated |
| AMR POCT B vs SC | GBP 269,519.00 (EUR 360,425.00) |
GBP 31.83 (EUR 42.57) |
436 | GBP 617.60 (EUR 825.91) |
0 | Dominated | |
| AMR POCT C vs SC | GBP 263,674.00 (EUR 352,608.50) |
GBP 31.14 (EUR 41.64) |
391 | GBP 674.71 (EUR 902.28) |
0 | Dominated | |
| AMR POCT D vs SC | GBP 91,956.00 (EUR 122,971.80) |
GBP 10.86 (EUR 14.52) |
271 | GBP 339.59 (EUR 454.13) |
7,938 | GBP 11.58 (EUR 15.49) |
|
| AMR POCT E vs SC | GBP 132,108.00 (EUR 176,666.70) |
GBP 15.60 (EUR 20.86) |
248 | GBP 533.21 (EUR 713.06) |
5,658 | GBP 23.35 (EUR 31.23) |
|
| Women | AMR POCT A vs SC | GBP 238,796.00 (EUR 319,339.40) |
GBP 28.13 (EUR 37.62) |
148 | GBP 1,612.62 (EUR 2,156.54) |
0 | Dominated |
| AMR POCT B vs SC | GBP 270,428.00 (EUR 361,640.60) |
GBP 31.86 (EUR 42.61) |
223 | GBP 1,210.74 (EUR 1,619.11) |
0 | Dominated | |
| AMR POCT C vs SC | GBP 263,339.00 (EUR 352,160.50) |
GBP 31.02 (EUR 41.48) |
194 | GBP 1,356.61 (EUR 1,814.18) |
0 | Dominated | |
| AMR POCT D vs SC | GBP 88,028.00 (EUR 117,718.90) |
GBP 10.37 (EUR 13.87) |
163 | GBP 540.55 (EUR 722.87) |
8,176 | GBP 10.77 (EUR 14.40) |
|
| AMR POCT E vs SC | GBP 110,386.00 (EUR 147,618.10) |
GBP 13.00 (EUR 17.38) |
148 | GBP 745.45 (EUR 996.88) |
6,714 | GBP 16.44 (EUR 21.99) |
AMR: antimicrobial resistance; MSM: men who have sex with men; MSW: men who have sex with women; POCT: point-of-care test; SC: standard care.
a GBP costs were converted to EUR using a historic currency conversion of an average of 366 days from 1 July 2015 to 30 June 2016 [48]. For this time period, GBP 1 = EUR 1.34, and EUR 1 = GBP 0.75.
A strategy is ‘dominated’ if it is more expensive and provides fewer/equivalent benefits.